Intestinal Ralstonia pickettii augments glucose intolerance in obesity

PLoS One. 2017 Nov 22;12(11):e0181693. doi: 10.1371/journal.pone.0181693. eCollection 2017.

Abstract

An altered intestinal microbiota composition has been implicated in the pathogenesis of metabolic disease including obesity and type 2 diabetes mellitus (T2DM). Low grade inflammation, potentially initiated by the intestinal microbiota, has been suggested to be a driving force in the development of insulin resistance in obesity. Here, we report that bacterial DNA is present in mesenteric adipose tissue of obese but otherwise healthy human subjects. Pyrosequencing of bacterial 16S rRNA genes revealed that DNA from the Gram-negative species Ralstonia was most prevalent. Interestingly, fecal abundance of Ralstonia pickettii was increased in obese subjects with pre-diabetes and T2DM. To assess if R. pickettii was causally involved in development of obesity and T2DM, we performed a proof-of-concept study in diet-induced obese (DIO) mice. Compared to vehicle-treated control mice, R. pickettii-treated DIO mice had reduced glucose tolerance. In addition, circulating levels of endotoxin were increased in R. pickettii-treated mice. In conclusion, this study suggests that intestinal Ralstonia is increased in obese human subjects with T2DM and reciprocally worsens glucose tolerance in DIO mice.

MeSH terms

  • Aged
  • Animals
  • DNA, Bacterial / analysis
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / microbiology
  • Diet, High-Fat
  • Feces / microbiology
  • Female
  • Glucose Intolerance / complications*
  • Glucose Intolerance / microbiology*
  • Gram-Negative Bacterial Infections / microbiology*
  • Gram-Negative Bacterial Infections / pathology
  • Humans
  • Inflammation / complications
  • Inflammation / pathology
  • Intestines / microbiology*
  • Intestines / pathology
  • Intra-Abdominal Fat / microbiology
  • Intra-Abdominal Fat / pathology
  • Male
  • Mice, Inbred C57BL
  • Obesity / complications*
  • Obesity / microbiology*
  • Ralstonia pickettii / physiology*

Substances

  • DNA, Bacterial

Grants and funding

F. Bäckhed is supported by Swedish Research Council, Swedish Diabetes Foundation, Swedish Heart Lung Foundation, Swedish Foundation for Strategic Research, Knut and Alice Wallenberg foundation, Göran Gustafsson Foundation, Ingbritt and Arne Lundberg's foundation, Swedish Heart Lung Foundation, Torsten Söderberg's Foundation, Ragnar Söderberg's Foundation, NovoNordisk Foundation, AFA insurances, and LUA-ALF grants from Västra Götalandsregionen and Stockholm County Council. P.D.Cani is a research associate from the FRS-FNRS in Belgium. P.D. Cani is the recipient of FRFS-WELBIO under grant: WELBIO-CR-2012S-02R, the Funds Baillet Latour (Grant for Medical Research 2015), and ERC Starting Grant 2013 (Starting grant 336452-ENIGMO). FB is a recipient of ERC Consolidator Grant (European Research Council, Consolidator grant 615362 - METABASE). WM de Vos is supported by the Finland Academy of Sciences (grants 137389, 141140 and 1272870), the Netherlands Organization for Scientific Research (Spinoza Award and SIAM Gravity Grant) and the European Research Council (ERC Advanced Grant 250172 MicrobesInside and a POC Grant 632241) M. Nieuwdorp is supported by a ZONMW-VIDI grant 2013 (016.146.327). F.B. and G.B. received support in the form of equity from MetaboGen AB, Sweden. M.N. and W.M.deV. received support in the form of equity from Scientific Advisory Board of Caelus Pharmaceutical. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.